Showing posts with label Drug Delivery. Show all posts
Showing posts with label Drug Delivery. Show all posts
Wednesday, 19 June 2013
Tuesday, 19 March 2013
Galena Biopharma Acquires Rights for sale and distribution of Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain
- Abstral® was approved in the U.S. in 2011 and is the first and only fentanyl sublingual tablet for the management of breakthrough cancer pain in opioid tolerant patients.
- Abstral® product launch targeted in the 4th Quarter of 2013.
- To fund the acquisition and product launch, Galena plans to enter into a non-dilutive debt financing of up to $15 million.
Capsugel acquires Encap Drug Delivery
Capsugel today announced that it has
acquired Encap Drug Delivery. Based in Scotland, Encap’s focus on liquid
and semi-solid encapsulation-based product development, and clinical
and commercial manufacturing for the pharmaceutical industry,
complements Capsugel’s recently-established Dosage Form Solutions (DFS)
business unit which develops and manufactures innovative products for
the healthcare industry.
Monday, 22 October 2012
Pfizer to acquire Nextwave pharmaceuticals
NEW YORK--(BUSINESS WIRE)--Pfizer
Inc. (NYSE: PFE) today announced its intention to acquire NextWave
Pharmaceuticals, a privately held, specialty pharmaceutical company
focused on the development and commercialization of unique products for
the treatment of attention deficit/hyperactivity disorder (ADHD) and
related central nervous system (CNS) disorders.
NextWave is the developer of Quillivant XR™ (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD, and holds exclusive North American commercialization rights to Quillivant XR. Quillivant XR received approval from the U.S. Food and Drug Administration on September 27, 2012, and is expected to be available in pharmacies in the U.S. in January 2013.
Quillivant XR was developed in collaboration with Tris Pharma, NextWave’s technology and manufacturing partner. Quillivant XR is built on Tris’ OralXR+ platform.
Pfizer had previously entered into an option and merger agreement with NextWave during the second quarter 2012 and made an option payment of $20 million. Today, Pfizer is exercising its option to acquire NextWave. Under the terms of the agreement, Pfizer will make a payment to of $255 million to NextWave’s shareholders at the closing of the transaction, and NextWave’s shareholders are eligible to receive additional payments of up to $425 million based on certain sales milestones.
“This agreement demonstrates our focused expansion of the Established Products U.S. brands business to offer a diverse portfolio of high-quality medicines that meet patients’ needs,” said Albert Bourla, president and general manager in Pfizer’s Established Products Business Unit. “By combining the advantages of Quillivant XR with Pfizer’s commercialization expertise, we will be able to provide ADHD patients and their caregivers a new treatment option.”
“NextWave has been focused on helping patients and families who struggle with the challenges of ADHD. We are excited to partner with Pfizer, one of the most respected pharmaceutical organizations in the world, to bring the unique benefits of Quillivant XR to those affected by this challenging condition,” said Jay P. Shepard, president and chief executive officer of NextWave.
NextWave is the developer of Quillivant XR™ (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD, and holds exclusive North American commercialization rights to Quillivant XR. Quillivant XR received approval from the U.S. Food and Drug Administration on September 27, 2012, and is expected to be available in pharmacies in the U.S. in January 2013.
Quillivant XR was developed in collaboration with Tris Pharma, NextWave’s technology and manufacturing partner. Quillivant XR is built on Tris’ OralXR+ platform.
Pfizer had previously entered into an option and merger agreement with NextWave during the second quarter 2012 and made an option payment of $20 million. Today, Pfizer is exercising its option to acquire NextWave. Under the terms of the agreement, Pfizer will make a payment to of $255 million to NextWave’s shareholders at the closing of the transaction, and NextWave’s shareholders are eligible to receive additional payments of up to $425 million based on certain sales milestones.
“This agreement demonstrates our focused expansion of the Established Products U.S. brands business to offer a diverse portfolio of high-quality medicines that meet patients’ needs,” said Albert Bourla, president and general manager in Pfizer’s Established Products Business Unit. “By combining the advantages of Quillivant XR with Pfizer’s commercialization expertise, we will be able to provide ADHD patients and their caregivers a new treatment option.”
“NextWave has been focused on helping patients and families who struggle with the challenges of ADHD. We are excited to partner with Pfizer, one of the most respected pharmaceutical organizations in the world, to bring the unique benefits of Quillivant XR to those affected by this challenging condition,” said Jay P. Shepard, president and chief executive officer of NextWave.
Octoplus Acquisition - Dr. Reddy expediting its presence in Value Added Generics
Dr. Reddy announced acquisition of Octoplus NV for a consideration of Euro 27.4 million. Octoplus has strengths in drug delivery, formulation and manufacturing based on proprietory technologies.
The most advanced product in Octoplus pipeline is Locteron ( an advanced version of PegInterferon) which requires less frequent administration (once every two weeks as compared to once weekly) and also causes fewer side effects (reduction in flu like symptoms and depression). Locteron is already partnered with Biolex. A Phase 2 b study has already been completed in 2011. Octoplus is most likely eligible for milestone payments, as soon as Phase 3 studies are initiated. Inteferons. The interferon, which are intended for the treatment of HCV comprise a $2billion market. With the expected entry of interferon free regime, there is uncertainty on the potential of Locteron and its value for Octoplus.
Besides Locteron, Octoplus is also in collaboration with Esbatech, an Alcon/Novartis division, for developing a controlled release formulation of an ophthalmic compound
Acquisition Rationale
In terms of valuation, Dr. Reddy has paid approximately 3x revenues. In 1H-2012, Octoplus generated revenues of Euro 4.8million. and net loss of euro 2.5 million.
Octoplus drug delivery and formulation technologies would very well complement Dr. Reddy's API and regulatory expertise, generic drug developmental skill and global reach. The acquisition makes tremendous strategic sense especially at a time when market for copy-cat oral formulations is getting increasingly commoditized.
The most advanced product in Octoplus pipeline is Locteron ( an advanced version of PegInterferon) which requires less frequent administration (once every two weeks as compared to once weekly) and also causes fewer side effects (reduction in flu like symptoms and depression). Locteron is already partnered with Biolex. A Phase 2 b study has already been completed in 2011. Octoplus is most likely eligible for milestone payments, as soon as Phase 3 studies are initiated. Inteferons. The interferon, which are intended for the treatment of HCV comprise a $2billion market. With the expected entry of interferon free regime, there is uncertainty on the potential of Locteron and its value for Octoplus.
Besides Locteron, Octoplus is also in collaboration with Esbatech, an Alcon/Novartis division, for developing a controlled release formulation of an ophthalmic compound
Acquisition Rationale
In terms of valuation, Dr. Reddy has paid approximately 3x revenues. In 1H-2012, Octoplus generated revenues of Euro 4.8million. and net loss of euro 2.5 million.
Octoplus drug delivery and formulation technologies would very well complement Dr. Reddy's API and regulatory expertise, generic drug developmental skill and global reach. The acquisition makes tremendous strategic sense especially at a time when market for copy-cat oral formulations is getting increasingly commoditized.
Subscribe to:
Posts (Atom)